SINGLE CENTRE SURVIVAL OUTCOMES IN THE TREATMENT OF INTERMEDIATE AND HIGH-RISK MYELODYSPLASTIC SYNDROME AND ACUTE MYELOID LEUKAEMIA WITH 5-AZACITIDINE

被引：0
|
作者：
Stringer, R. [1 ]
Rider, D. T. [2 ]
Newman, D. J. [2 ]
Grace, D. R. [2 ]
机构：
[1] Brighton & Sussex Med Sch, Brighton, E Sussex, England
[2] East Sussex Healthcare NHS Trust, Eastbourne, England
来源：
HAEMATOLOGICA | 2015年 / 100卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PB1835
引用
收藏
页码：725 / 726
页数：2
相关论文
共 50 条
  • [31] Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure
    Prebet, Thomas
    Gore, Steven D.
    Esterni, Benjamin
    Gardin, Claude
    Itzykson, Raphael
    Thepot, Sylvain
    Dreyfus, Francois
    Rauzy, Odile Beyne
    Recher, Christian
    Ades, Lionel
    Quesnel, Bruno
    Beach, C. L.
    Fenaux, Pierre
    Vey, Norbert
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (24) : 3322 - 3327
  • [32] Antifungal prophylaxis in acute myeloid leukemia and high-risk myelodysplastic patients: a single centre experience
    Bergantim, R. B.
    Carvalhais, I.
    Trigo, F.
    Guimaraes, J. E.
    MYCOSES, 2009, 52 : 114 - 114
  • [33] 5-AZACITIDINE TREATMENT RESTORES RESPONSE TO EPOETIN THERAPY IN HIGH RISK MYELODYSPLASTIC (MDS) PATIENTS
    Volpe, M.
    Volpe, A.
    HAEMATOLOGICA, 2012, 97 : 588 - 589
  • [34] The Prognostic Value of Monosomal Karyotype (MK) in High-Risk Patients with Myelodysplastic Syndromes Treated with 5-Azacitidine
    Papageorgiou, Sotirios
    Kontos, Christos K.
    Tsiambalis, Thomas
    Vyniou, Athina
    Symeonidis, Argiris
    Galanopoulos, Athanasios
    Kotsianidis, Ioannis
    Pappa, Vassiliki
    BLOOD, 2017, 130
  • [35] Bone marrow mononuclear cell telomere length in acute myeloid leukaemia and high-risk myelodysplastic syndrome
    Warny, Marie
    Helby, Jens
    Sengelov, Henrik
    Nordestgaard, Borge G.
    Birgens, Henrik
    Bojesen, Stig E.
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2019, 102 (03) : 218 - 226
  • [36] EXPERIENCE WITH 5-AZACITIDINE TREATMENT IN PATIENTS WITH ATYPICAL CHRONIC MYELOID LEUKAEMIA (PH NEGATIVE)
    Amoros, C.
    Javier, K.
    Costa, S.
    Marin, M.
    Linares, M.
    HAEMATOLOGICA, 2018, 103 : 347 - 347
  • [37] DNA Methylation Changes Following 5-azacitidine Treatment in Patients with Myelodysplastic Syndrome
    Huong Thi Thanh Tran
    Kim, Hee Nam
    Lee, Il-Kwon
    Kim, Yeo-Kyeoung
    Ahn, Jae-Sook
    Yang, Deok-Hwan
    Lee, Je-Jung
    Kim, Hyeoung-Joon
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2011, 26 (02) : 207 - 213
  • [38] DNA Methylation Changes Following 5-Azacitidine Treatment in Patients with Myelodysplastic Syndrome
    Tran, Huong Thi Thanh
    Kim, Hee Nam
    Kim, Yeo-Kyeoung
    Ahn, Jae-Sook
    Lee, Il-Kwon
    Yang, Deok-Hwan
    Lee, Je-Jung
    Hoon, Kook
    Hwang, Tai Ju
    Kim, Hyeoung-Joon
    BLOOD, 2009, 114 (22) : 1091 - 1092
  • [39] Late Hematological Improvement of Myelodysplastic Syndrome Following Treatment with 5-Azacitidine Therapy
    Takaoka, Kensuke
    Hangaishi, Akira
    Ito, Ayumu
    Morioka, Takehiko
    Kida, Michiko
    Usuki, Kensuke
    INTERNAL MEDICINE, 2014, 53 (19) : 2241 - 2243
  • [40] NICE guidance on azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia, and acute myeloid leukaemia
    Miller, Whitney
    Holden, Joanne
    George, Elisabeth
    Stein, Ken
    LANCET ONCOLOGY, 2011, 12 (04): : 326 - 327
12345